Aptevo Therapeutics, a biotech company, is at the forefront of developing five bispecific antibodies designed for both blood and solid tumors. Currently, two of these antibodies are undergoing clinical trials, while the remaining three are in the preclinical stages. This innovative approach holds great promise in the field of therapeutics, offering potential new treatment options […]
Tag: bispecific
Yann Echelard Sells $369K of TG Therapeutics Stock
As a rising star in the biopharmaceutical landscape, TG Therapeutics Inc solidifies its standing as an innovative game-changer in the battle against B-cell diseases. The recent FDA approval of BRIUMVI for managing relapsing multiple sclerosis further underscores the company’s commitment to spearheading the development and commercialization of novel therapies that reshape the treatment paradigm. TG […]
Cancer Bispecific Antibody Collaboration Accelerates Market Entry
The collaboration between BMS and BioNTech, valued up to $11B, aims to expedite BNT327’s market launch and mitigate risks in various settings. This partnership provides BNTX with non-dilutive capital, fortifying its oncology pipeline. Despite modest overall survival hazard ratios compared to progression-free survival, this deal affirms the asset’s value and enhances BNTX’s financial standing for […]